Ulisse Biomed S.p.A. (UBM.MI)
EUR 0.78
(0.0%)
EUR 0.78
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -3.45 Million EUR | -193.74% |
| 2022 | -1.7 Million EUR | -130.31% |
| 2021 | -738.35 Thousand EUR | -715.29% |
| 2020 | 120 Thousand EUR | 110.75% |
| 2019 | -1.11 Million EUR | 40.08% |
| 2018 | -1.86 Million EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -825.22 Thousand EUR | 0.0% |
| 2024 Q1 | -825.22 Thousand EUR | 38.31% |
| 2023 FY | -4.99 Million EUR | -193.74% |
| 2023 Q3 | -1.97 Million EUR | -104.03% |
| 2023 Q4 | -1.33 Million EUR | 32.25% |
| 2023 Q2 | -967.71 Thousand EUR | -115.18% |
| 2023 Q1 | -449.72 Thousand EUR | 50.74% |
| 2022 Q2 | -787.52 Thousand EUR | -196.99% |
| 2022 FY | -1.7 Million EUR | -130.31% |
| 2022 Q3 | -441.32 Thousand EUR | 43.96% |
| 2022 Q1 | -265.16 Thousand EUR | 58.87% |
| 2022 Q4 | -912.95 Thousand EUR | -106.87% |
| 2021 FY | -738.35 Thousand EUR | -715.29% |
| 2021 Q1 | -44.12 Thousand EUR | -121.09% |
| 2021 Q2 | -93.66 Thousand EUR | -112.24% |
| 2021 Q3 | -257.59 Thousand EUR | -175.03% |
| 2021 Q4 | -644.69 Thousand EUR | -150.28% |
| 2020 Q2 | -247.91 Thousand EUR | -945.64% |
| 2020 FY | 120 Thousand EUR | 110.75% |
| 2020 Q3 | 135.82 Thousand EUR | 154.79% |
| 2020 Q1 | -23.7 Thousand EUR | 0.0% |
| 2020 Q4 | 209.21 Thousand EUR | 54.03% |
| 2019 FY | -1.11 Million EUR | 40.08% |
| 2018 FY | -1.86 Million EUR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| ARTERRA BIOSCIENCE | -1.53 Million EUR | -125.532% |
| Philogen S.p.A. | -8.84 Million EUR | 60.87% |